令和の心不全治療ガイド

出版社： 文光堂
著者：
発行日： 2022-03-01
分野： 臨床医学：内科  >  循環器一般
ISBN： 9784830619694
電子書籍版： 2022-03-01 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,700 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,700 円(税込)

購入する

商品紹介

近年，心不全患者は増加の一途を辿り，同時に新規治療薬が続々と登場し，治療にも大きな変化が起こった．本書では，そんな変化の激しい心不全診療についていけないという声に応えて，最新の知識を効率よくアップデートできるよう要点を絞って解説した．現在の治療戦略の考え方から，在宅医療，心不全緩和ケアの話題まで，最新のガイドラインのさらに一歩先に行く内容も含めて記載した．心不全診療に携わる医師，メディカルスタッフは必携の一冊．

目次

  • 総説

    I　HFrEFの治療up to date
    　A　HFrEFに対する最新の治療戦略
    　B　HFrEFの治療効果の判定には何を用いる？
    　C　HFrEFの心拍管理におけるイバブラジンの使い方
    　D　sGC刺激薬（ベルイシグアト）の作用機序と臨床エビデンス　
    　E　HFrEFの機能性MR―to clip or not to clip
    　F　HFmrEFとは何者か？ 治療はどのようにすべきか？
    　G　CRTの有効性を上げる工夫，そしてCRT-P or CRT-Dの選択
    　H　重症HFrEFの抗血栓療法はどうすべきか？
    　I　高カリウム血症は本当にリスクなのか？―正常値の考え方と対処法up to date
    　J　心臓移植とdestination therapyの現在地

    II　HFpEFの治療up to date
    　A　HFpEFとは何者か？ 機序とphenotypeを考える
    　B　HFpEFに対する最新の治療戦略

    III　急性期の心不全治療
    　A　クリニカルシナリオに基づく急性心不全治療のノウハウ
    　B　急性期に体液貯留を解除する―ループ利尿薬だけではない賢い体液管理
    　C　超重症心不全の補助循環―IABP，PCPS（ECMO），IMPELLA，体外設置型VAD
    　D　心不全急性期からの栄養補給をどうすべきか？

    IV　心不全と不整脈の密接な見解
    　A　心臓突然死を予防する治療薬
    　B　心房細動に対するアブレーション治療―合併症例の適応は拡大している
    　C　心室期外収縮との因果関係と治療を探る
    　D　心室頻拍に対する最新の治療コンセプト
    　E　ICDの適応を考える―S-ICDはどのような患者が対象になるか？

    V　心筋疾患による心不全を見逃さない
    　A　ATTR心アミロイドーシスを見つける，治療する
    　B　Fabry病を見つける，治療する
    　C　心臓サルコイドーシスを診断し，治療する
    　D　ハイリスク肥大型心筋症を見つける，治療する
    　E　稀だが覚えておくべき心筋疾患
    　F　たこつぼ心筋症（たこつぼ症候群）up to date
    　G　周産期心筋症とはどのようなものか？―診断と治療up to date
    　H　がん治療に伴う心不全とはどのようなものか？―診断と治療up to date
    　I　急性そして劇症型心筋炎を診断し，治療する

    VI　合併症とその治療戦略
    　A　糖尿病患者の心不全発症予防，糖尿病治療薬の選択は？
    　B　高血圧患者ステージA，Bの治療戦略
    　C　貧血と鉄欠乏―鉄剤とHIF-PH阻害薬
    　D　慢性腎不全患者の心不全治療薬の選択は？
    　E　大動脈弁狭窄症に対するTAVI―超高齢であればすべて適応か？
    　F　心不全患者における漢方の役割
    　G　睡眠呼吸障害へのアプローチup to date
    　H　非心臓手術における心不全患者の適応をどうするか？

    VII　心不全再入院を予防する治療戦略
    　A　体液貯留を理解する―なぜ，心不全増悪と再入院の原因になるのか？
    　B　急性・慢性心不全の体液貯留を治療し，予防する
    　C　慢性期の心臓リハビリテーションをどのように継続して行うか？
    　D　心不全患者をかかりつけ医がみるときに重要なポイントは？
    　E　在宅患者の心不全治療は可能であるか？
    　F　心不全診療における心不全療養指導士の役割
    　G　advance care planning（ACP）と緩和ケアの実際
    　H　遠隔モニタリングと遠隔診療はどのようにすればよいのか？

    VIII　心不全診療で活かす検査
    　A　MDCTを活用する
    　B　MRIを活用する
    　C　心筋シンチグラフィを活用する
    　D　心エコー指標を慢性心不全の診療に活用する
    　E　心不全診療に活かす心肺運動負荷試験，6分間歩行距離
    　F　この血液検査は見逃すな
    　G　確定診断に欠かせない心筋生検
    　H　心不全でこそ活きる血行動態の理解

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

総説

P.5 掲載の参考文献
1) Ejiri, K et al : Unprecedented crisis-heart failure hospitalizations in current or future Japan. J Cardiol 74 : 426-427, 2019
PubMed
2) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年9月閲覧)
 
3) 厚生労働省 : 脳卒中, 心臓病その他の循環器病に係る診療提供体制の在り方に関する検討会 : 脳卒中, 心臓病その他の循環器病に係る診療提供体制の在り方について. 2017. https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000173149.pdf (2020年1月閲覧)
 
4) Greene, SJ et al : Quadruple medical therapy for heart failure : medications working together to provide the best care. J Am Coll Cardiol 77 : 1408-1411, 2021
 
5) Boorsma, EM et al : Congestion in heart failure : a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 17 : 641-655, 2020
 

I HFrEFの治療up to date

P.14 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
2) 日本循環器学会/日本心不全学会 : 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2021年10月閲覧)
 
3) McDonagh, TA et al : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
4) Bozkurt, B et al : Universal definition and classification of heart failure : a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail 1 : S1071-9164 (21) 00050-6, 2021
 
5) Bozkurt, B et al : Universal definition and classification of heart failure : a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure : Endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail 23 : 352-380, 2021
 
6) Maddox, TM et al : 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment : Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction : A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77 : 772-810, 2021
 
P.17 掲載の参考文献
1) 日本心不全学会予防委員会 : 血中BNPやNT-proBNP値を用いた心不全診療の留意点について. http://www.asas.or.jp/jhfs/topics/bnp201300403.html (2022年1月閲覧)
 
2) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_d.pdf (2021年10月閲覧)
 
3) Pfisterer, M et al : BNP-guided vs symptom-guided heart failure therapy : the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301 : 383-392, 2009
PubMed
4) Myhre, PL et al : B-type natriuretic peptide during treatment with sacubitril/valsartan : The PARADIGM-HF trial. J Am Coll Cardiol 73 : 1264-1272, 2019
 
5) Tsuji, K et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 Study. Eur J Heart Fail 19 : 1258-1269, 2017
 
6) Savarese, G et al : Prevalence and prognostic implications of longitudinal ejection fraction change in heart failure. JACC Heart Fail 7 : 306-317, 2019
PubMed
7) Punnoose, LR et al : Heart failure with recovered ejection fraction : a distinct clinical entity. J Card Fail 17 : 527-532, 2011
PubMed
8) Clarke, CL et al : Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes 6 : 680-686, 2013
PubMed
9) 日本循環器学会/日本心不全学会 : 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2022年1月閲覧)
 
10) Halliday, BP et al : Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF) : an open-label, pilot, randomised trial. Lancet 393 : 61-73, 2019
PubMed
11) Januzzi, JL Jr et al : Association of change in N-terminal Pro-Btype natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction. JAMA 322 : 1085-1095, 2019
 
12) Barsheshet, A et al : Reverse remodeling and the risk of ventricular tachyarrhythmias in the MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy). J Am Coll Cardiol 57 : 2416-2423, 2011
PubMed
P.23 掲載の参考文献
1) Levine, HJ : Rest heart rate and life expectancy. J Am Coll Cardiol 30 : 1104-1106, 1997
PubMed
2) Lechat, P et al : Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation 103 : 1428-1433, 2001
PubMed
3) Swedberg, K et al : Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo-controlled study. Lancet 376 : 875-885, 2010
PubMed
4) Tsutsui, H et al : Efficacy and safety of ivabradine in Japanese patients with chronic heart failure-J-SHIFT study. Circ J 83 : 2049-2060, 2019
PubMed
5) Sunagawa, K et al : Ventricular interaction with the loading system. Ann Biomed Eng 12 : 163-189, 1984
PubMed
6) Maughan, WL et al : Effect of heart rate on the canine end-systolic pressure-volume relationship. Circulation 72 : 654-659, 1985
PubMed
7) Tanaka, N et al : Heart-rate-proportional oxygen consumption for constant cardiac work in dog heart. Jpn J Physiol 40 : 503-521, 1990
PubMed
8) Liu, CP et al : Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants. Circulation 88 : 1893-1906, 1993
PubMed
9) Hay, I et al : Role of impaired myocardial relaxation in the production of elevated left ventricular filling pressure. Am J Physiol Heart Circ Physiol 288 : H1203-H1208, 2005
PubMed
10) Heusch, G : Heart rate and heart failure. Not a simple relationship. Circulation 75 : 229-236, 2011
 
11) Messerli, FH et al : When an increase in central systolic pressure overrides the benefits of heart rate lowering. J Am Coll Cardiol 68 : 754-762, 2016
PubMed
12) Zugck, C et al : Ivabradine improves symptoms and quality of life in chronic systolic heart failure patients with different baseline symptom severity. J Card Fail 21 : s46, 2015
 
13) Koitabashi, N et al : Reverse remodeling in heart failure―mechanisms and therapeutic opportunities. Nat Rev Cardiol 9 : 147-157, 2011
 
14) Miura, M et al : Usefulness of combined risk stratification with heart rate and systolic blood pressure in the management of chronic heart failure. A report from the CHART-2 study. Circ J 77 : 2954-2962, 2013
PubMed
15) Milliez, P et al : Beneficial effects of delayed ivabradine treatment on cardiac anatomical and electrical remodeling in rat severe chronic heart failure. Am J Physiol Heart Circ Physiol 296 : H435-H441, 2009
PubMed
16) Reil, J et al : Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 62 : 1977-1985, 2013
PubMed
17) Colin, P et al : Contributions of heart rate and contractility to myocardial oxygen balance during exercise. Am J Physiol Heart Circ Physiol 284 : H676-H682, 2003
PubMed
18) Kumakura, S et al : Effects of beta blockers on cardiac function and myocardial oxygen consumption in the isolated supported heart preparation of the dog. Jpn Heart J 16 : 592-602, 1975
PubMed
19) Hidalgo, FJ et al : Effect of early treatment with ivabradine combined with beta-blockers versus beta-blockers alone in patients hospitalised with heart failure and reduced left ventricular ejection fraction (ETHIC-AHF) : A randomised study. Int J Cardiol 217 : 7-11, 2016
PubMed
20) Izco, MP et al : Ivabradine in acute heart failure : effects on heart rate and hemodynamic parameters in a randomized and controlled swine trial. Cardiol J 27 : 62-71, 2020
 
21) Su, Y et al : Efficacy of early initiation of ivabradine treatment in patients with acute heart failure : rationale and design of SHIFT-AHF trial. ESC Heart Fail 7 : 4465-4471, 2020
 
22) Cavusoglu, Y et al : Ivabradine treatment prevents dobutamine-induced increase in heart rate in patients with acute decompensated heart failure. J Cardiovasc Med 16 : 603-609, 2015
 
23) Sunagawa, G et al : Mechano-chronotropic unloading during the acute phase of myocardial infarction markedly reduces infarct size via the suppression of myocardial oxygen consumption. J Cardiovasc Transl Res 12 : 124-134, 2019
PubMed
P.29 掲載の参考文献
1) Gheorghiade, M et al : Soluble guanylate cyclase : a potential therapeutic target for heart failure. Heart Fail Rev 18 : 123-134, 2013
PubMed
2) Evgenov, OV et al : NO-independent stimulators and activators of soluble guanylate cyclase : discovery and therapeutic potential. Nat Rev Drug Discov 5 : 755-768, 2006
PubMed
3) Bonderman, D et al : Riociguat for patients with pulmonary hypertension caused by systolic left ventricular dysfunction : a phase IIb double-blind, randomized, placebo-controlled, dose-ranging hemodynamic study. Circulation 128 : 502-511, 2013
PubMed
4) Gheorghiade, M et al : Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction : The SOCRATES-REDUCED randomized trial. JAMA 314 : 2251-2262, 2015
PubMed
5) Armstrong, PW et al : Vericiguat in patients with heart failure and reduced ejection fraction. N Eng J Med 382 : 1883-1893, 2020
 
6) Ezekowitz, JA et al : N-terminal Pro-B-type natriuretic peptide and clinical outcomes : vericiguat heart failure with reduced ejection fraction study. JACC Heart Fail 8 : 931-939, 2020
 
P.33 掲載の参考文献
1) Koelling, TM et al : Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J 144 : 524-529, 2002
PubMed
2) Grigioni, F et al : Ischemic mitral regurgitation : long-term outcome and prognostic implications with quantitative doppler assessment. Circulation 103 : 1759-1764, 2001
PubMed
3) Bach, DS et al : Failure of guideline adherence for intervention in patients with severe mitral regurgitation. J Am Coll Cardiol 54 : 860-865, 2009
PubMed
4) Obadia, JF et al : Percutaneous repair or medical treatment for secondary mitral regurgitation. N Engl J Med 379 : 2297-2306, 2018
 
5) Stone, GW et al : Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med 379 : 2307-2318, 2018
PubMed
6) Izumi, C et al : JCS/JSCS/JATS/JSVS 2020 guidelines on the management of valvular heart disease. Circ J 84 : 2037-2119, 2020
PubMed
7) Otto, CM et al : 2020 ACC/AHA guideline for the management of patients with valvular heart disease : A report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation 143 : e72-e227, 2021
 
8) Pibarot, P et al : MITRA-FR vs. COAPT : lessons from two trials with diametrically opposed results. Eur Heart J Cardiovasc Imaging 20 : 620-624, 2019
PubMed
9) Lancellotti, P et al : Long-term outcome of patients with heart failure and dynamic functional mitral regurgitation. Eur Heart J 26 : 1528-1532, 2005
PubMed
P.38 掲載の参考文献
1) Ponikowski, P et al : 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure : The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 18 : 891-975, 2016
 
2) Chung, AK et al : Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume : the Dallas Heart Study. Circulation 113 : 1597-1604, 2006
PubMed
3) Konstam, MA : Seeking therapeutic precision in heart failure : is ejection fraction really the way? Deconstructing the CHARM of heart failure with mid-range ejection fraction. Eur J Heart Fail 20 : 1240-1242, 2018
PubMed
4) McMurray, JJV et al : Heart failure. Lancet 365 : 1877-1889, 2005
 
5) Fonarow, GC et al : Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure : a report from the OPTIMIZE-HF registry. J Am Coll Cardiol 50 : 768-777, 2007
PubMed
6) Yusuf, S et al : Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction : the CHARM-Preserved trial. Lancet 362 : 777-781, 2003
PubMed
7) Lund, LH et al : Heart failure with mid-range ejection fraction in CHARM : characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail 20 : 1230-1239, 2018
PubMed
8) McMurray, JJV et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014
 
9) Solomon, SD et al : Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381 : 1609-1620, 2019
PubMed
10) McMurray, JJV et al : Effects of sacubitril-valsartan versus valsartan in women compared with men with heart failure and preserved ejection fraction : insights from PARAGON-HF. Circulation 141 : 338-351, 2020
PubMed
11) McDonagh, TA et al : 2021 ESC guideline for the diagonosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
 
12) McMurray JJV et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
13) Packer, M et al : Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383 : 1413-1424, 2020
PubMed
14) Tsutsui, H et al : JCS/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure, Circ J 85 : 2252-2291, 2021
PubMed
15) Anker, SD et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
16) Tsuji, K et al : Characterization of heart failure patients with mid-range left ventricular ejection fraction-a report from the CHART-2 study. Eur J Heart Fail 19 : 1258-1269, 2017
 
17) Melenovsky, V et al : Left atrial remodeling and function in advanced heart failure with preserved or reduced ejection fraction. Circ Heart Fail 8 : 295-303, 2015
 
18) Saikhan, LA et al : Left atrial function in heart failure with midrange ejection fraction differs from that of heart failure with preserved ejection fraction : a 2D speckle-tracking echocardiographic study. Eur Heart J Cardiovasc Imaging 20 : 279-290, 2019
 
19) Zafrir, B et al : Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction : a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. Eur Heart J 39 : 4277-4284, 2018
 
P.43 掲載の参考文献
1) Mullens, W et al : Insights from a cardiac resynchronization optimization clinic as part of a heart failure disease management program. J Am Coll Cardiol 53 : 765-773, 2009
 
2) Mullens, W et al : Persistent hemodynamic benefits of cardiac resynchronization therapy with disease progression in advanced heart failure. J Am Coll Cardiol 53 : 600-607, 2009
PubMed
3) Chapman, M et al : A novel quadripolar active fixation left-ventricular pacing lead for cardiac resynchronization therapy : Initial United Kingdom experience. JACC Clin Electrophysiol 5 : 1028-1035, 2019
 
4) Adler, S et al : Two-year extractability of novel left ventricular, active fixation leads in the sheep model. Pacing Clin Electrophysiol 40 : 1291-1297, 2017
PubMed
5) Pappone, C et al : Improving cardiac resynchronization therapy response with multipoint left ventricular pacing : twelve-month follow-up study. Heart Rhythm 12 : 1250-1258, 2015
PubMed
6) Birnie, D et al : Clinical outcomes with synchronized left ventricular pacing : analysis of the adaptive CRT trial. Heart Rhythm 10 : 1368-1374, 2013
PubMed
7) Carson, P et al : Mode of death in advanced heart failure : the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. J Am Coll Cardiol 46 : 2329-2334, 2005
 
8) Barra, S et al : Adding defibrillation therapy to cardiac resynchronization on the basis of the myocardial substrate. J Am Coll Cardiol 69 : 1669-1678, 2017
PubMed
9) Gras, Met al : Mortality and cardiac resynchronization therapy with or without defibrillation in primary prevention. Europace 22 : 1224-1233, 2020
PubMed
10) Sieniewicz, BJ et al : Real-world experience of leadless left ventricular endocardial cardiac resynchronization therapy : A multicenter international registry of the WiSE-CRT pacing system. Heart Rhythm 17 : 1291-1297, 2020
PubMed
P.46 掲載の参考文献
1) Loh, E et al : Ventricular dysfunction and the risk of stroke after myocardial infarction. N Engl J Med 336 : 251-257, 1997
PubMed
2) Witt, BJ et al : Ischemic stroke after heart failure : a community-based study. Am Heart J 152 : 102-109, 2006
PubMed
3) Lip, GY et al : Does heart failure confer a hypercoagulable state? Virchow's triad revisited. J Am Coll Cardiol 33 : 1424-1426, 1999
 
4) Iguchi, M et al : Incidence and risk factors of stroke or systemic embolism in patients with atrial fibrillation and heart failure-the Fushimi AF registry. Circ J 82 : 1327-1335, 2018
 
5) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
6) McDonagh, TA et al : 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
7) Nakano, H et al : Current practice and effects of intravenous anticoagulant therapy in hospitalized acute heart failure patients with sinus rhythm. Sci Rep 11 : 1202, 2021
PubMed
8) Hamatani, Y et al : Elevated plasma D-dimer level is associated with short-term risk of ischemic stroke in patients with acute heart failure. Stroke 49 : 1737-1740, 2018
PubMed
9) Vemmos, K et al : Stroke aetiology and predictors of outcome in patients with heart failure and acute stroke : a 10-year follow-up study. Eur J Heart Fail 14 : 211-218, 2012
PubMed
10) 日本循環器学会/日本不整脈心電学会 : 2020年改訂版 不整脈薬物治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (2021年10月閲覧)
 
11) Savarese, G et al : Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure : a meta-analysis. JACC Heart Fail 4 : 870-880, 2016
PubMed
12) Homma, S et al : Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 366 : 1859-1869, 2012
PubMed
13) Zannad, F et al : Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 379 : 1332-1342, 2018
PubMed
14) Beggs, SAS et al : Anticoagulation therapy in heart failure and sinus rhythm : a systematic review and meta-analysis. Heart 105 : 1325-1334, 2019
PubMed
15) McCarthy, CP et al : Left ventricular thrombus : contemporary etiologies, treatment strategies, and outcomes. J Am Coll Cardiol 73 : 2007-2009, 2019
PubMed
16) Robinson, AA et al : Off-label use of direct oral anticoagulants compared with warfarin for left ventricular thrombi. JAMA Cardiol 5 : 685-692, 2020
PubMed
P.49 掲載の参考文献
1) Ferreira, JP et al : Abnormalities of potassium in heart failure : JACC state-of-the-art review. J Am Coll Cardiol 75 : 2836-2850, 2020
PubMed
2) Juurlink, DN et al : Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351 : 543-551, 2004
PubMed
3) Komajda, M et al : Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction : data from the QUALIFY global survey. Eur J Heart Fail 18 : 514-522, 2016
PubMed
4) Kashihara, N et al : Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Rep 4 : 1248-1260, 2019
PubMed
5) 日本腎臓学会 : エビデンスに基づくCKD診療ガイドライン 2018. https://cdn.jsn.or.jp/data/CKD2018.pdf (2021年10月閲覧)
 
6) Vardeny, O et al : Incidence, predictors, and outcomes related to hypo and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist. Circ Heart Fail 7 : 573-579, 2014
PubMed
7) Trevisan, M et al : Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail 20 : 1217-1226, 2018
 
8) Fu, EL et al : Stopping renin-angiotensin system inhibitors in patients with advanced CKD and risk of adverse outcomes : a nationwide study. J Am Soc Nephrol 32 : 424-435, 2021
PubMed
9) Rossignol, P et al : Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP heart failure long-term registry. Eur J Heart Fail 8 : 1378-1389, 2020
PubMed
10) 文部科学省 : 日本食品標準成分表 2020年版 (八訂). https://www.mext.go.jp/a_menu/syokuhinseibun/mext_01110.html (2022年1月閲覧).
 
P.57 掲載の参考文献
1) 日本胸部外科学会J-MACS委員会 : 日本における補助人工心臓に関連した市販後のデータ収集, 2021年3月. https://www.jpats.org/lib/files/society/jmacs/statistical_report_201006-202012.pdf (2021年12月閲覧)
 
2) 日本心臓移植研究会 : 心臓移植レジストリ報告. http://www.jsht.jp/2021/04/17/registry/japan/20201231レジストリ2.pdf (2021年12月閲覧)
 
3) The International Society for Heart and Lung Transplantation (ISHLT) : International Thoracic Organ Transplant (TTX) Registry Data Slides : 2019 Slides : Overall Heart Transplantation Statistics. https://ishltregistries.org/registries/slides.asp?yearToDisplay=2019 (2021年12月閲覧)
 
4) Kinugawa, K et al : Consensus Report on Destination Therapy in Japan-from the DT Committee of the Council for Clinical Use of Ventricular Assist Device Related Academic Societies. Circ J 85 : 1906-1917, 2021.
 
5) 補助人工心臓治療関連学会協議会 : 「植込型補助人工心臓」DT実施基準 (2021.3.19 策定). https://j-vad.jp/dt-lvad/ (2021年12月閲覧)
 
6) 日本臨床補助人工心臓研究会 : 植込み型補助人工心臓実施施設一覧 (成人), 2020年6月. https://www.jacvas.com/list/1/01/ (2021年12月閲覧)
 
7) 日本臨床補助人工心臓研究会 : 植込型補助人工心臓の使用に係る体制等の基準案について, 2010年11月. https://www.jacvas.com/application/2/standard/ (2021年12月閲覧)
 
8) 日本循環器学会/日本心臓血管外科学会/日本胸部外科学会/日本血管外科学会 : 2021年改訂版 重症心不全に対する植込型補助人工心臓治療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Ono_Yamaguchi.pdf (2021年12月閲覧)
 
9) Streur, MM et al : Left ventricular assist device caregiver experiences and health outcomes : a systematic review of qualitative and quantitative studies. J Card Fail 26 : 713-726, 2020
PubMed
10) Nakagawa, S et al : Association between "Unacceptable Condition" expressed in palliative care consultation before left ventricular assist device implantation and care received at the end of life. J Pain Symptom Manage 60 : 976-983.e1, 2020
 

II HFpEFの治療up to date

P.65 掲載の参考文献
1) Dunlay, SM et al : Advanced heart failure epidemiology and outcomes : a population-based study. JACC Heart Fail 9 : 722-732, 2021
PubMed
2) Ather, S et al : Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 59 : 998-1005, 2012
 
3) Desai AS, et al : Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36 : 1990-1997, 2015
PubMed
4) Nagai T, et al : Clinical Characteristics, Management, and Outcomes of Japanese Patients Hospitalized for Heart Failure With Preserved Ejection Fraction-A Report From the Japanese Heart Failure Syndrome With Preserved Ejection Fraction (JASPER) Registry. Circ J 82 : 1534-1545, 2018
PubMed
5) Kinugasa Y, et al : Carnitine insufficiency is associated with adverse outcomes in patients with heart failure with preserved ejection fraction. J Aging Res Clin Practice 5 : 187-193, 2016
 
6) Kinugasa, Y et al : l-Carnitine supplementation in heart failure patients with preserved ejection fraction ; a pilot study. Geriatr Gerontol Int 20 : 1244-1245, 2020
PubMed
7) Hirabayashi, K et al : Intramyocellular lipid is increased in the skeletal muscle of patients with dilated cardiomyopathy with lowered exercise capacity. Int J Cardiol 176 : 1110-1112, 2014
PubMed
8) Kinugasa, Y et al : Trimethylamine N-oxide and outcomes in patients hospitalized with acute heart failure and preserved ejection fraction. ESC Heart Fail 8 : 2103-2110, 2021
PubMed
9) Yamada, K et al : Inspiratory muscle weakness is associated with exercise intolerance in patients with heart failure with preserved ejection fraction : a preliminary study. J Card Fail 22 : 38-47, 2016
PubMed
10) Kinugasa Y, et al : Home-based inspiratory muscle training in patients with heart failure and preserved ejection fraction : a preliminary study. J Card Fail 26 : 1022-1023, 2020
PubMed
11) Yanagihara, K et al : Child ego state and self-care behavior change in heart failure patients. J Cardiol 78 : 294-300, 2021
PubMed
12) Hamdani, N et al : Leveraging clinical epigenetics in heart failure with preserved ejection fraction : a call for individualized therapies. Eur Heart J 42 : 1940-1958, 2021
 
13) Galli, E et al : Phenomapping heart failure with preserved ejection fraction using machine learning cluster analysis : prognostic and therapeutic implications. Heart Fail Clin 17 : 499-518, 2021
PubMed
14) Anker SD, et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
P.69 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2021年10月閲覧)
 
2) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年12月閲覧)
 
3) Pitt, B et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014
PubMed
4) Pfeffer, MA et al : Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT) trial. Circulation 131 : 34-42, 2015
PubMed
5) Solomon, SD et al : Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med 381 : 1609-1620, 2019
PubMed
6) Ibrahim, NE et al : Effect of neprilysin inhibition on various natriuretic peptide assays. J Am Coll Cardiol 73 : 1273-1284, 2019
PubMed
7) Anker, SD et al : Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 385 : 1451-1461, 2021
PubMed
8) Kosmala, W et al : Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction : a randomized trial. J Am Coll Cardiol 62 : 1330-1338, 2013
 
9) Pal, N et al : Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 132 : 1719-1725, 2015
PubMed
10) Fukuta, H et al : Statin therapy may be associated with lower mortality in patients with diastolic heart failure : a preliminary report. Circulation 112 : 357-363, 2005
PubMed
11) Tavazzi, L et al : Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial) : a randomised, double-blind, placebo controlled trial. Lancet 372 : 1231-1239, 2008
 

III 急性期の心不全治療

P.75 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
2) Mebazaa, A et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 (1 Suppl) : S129-S139, 2008
PubMed
3) Iakobishvili, Z et al : Use of intravenous morphine for acute decompensated heart failure in patients with and without acute coronary syndromes. Acute Card Care 13 : 76-80, 2011
PubMed
4) Matsue, Y et al : Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 69 : 3042-3051, 2017
PubMed
5) Webb, JG et al : Implications of the timing of onset of cardiogenic shock after acute myocardial infarction : a report from the SHOCK Trial Registry. Should we emergently revascularize occluded coronaries for cardiogenic shock? J Am Coll Cardiol 36 : 1084-1090, 2000
PubMed
6) Abraham, WT et al : In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications : an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 46 : 57-64, 2005
 
7) Levy, B et al : Comparison of norepinephrine-dobutamine to epinephrine for hemodynamics, lactate metabolism, and organ function variables in cardiogenic shock. A prospective, randomized pilot study. Crit Care Med 39 : 450-455, 2011
PubMed
P.80 掲載の参考文献
1) Desai, AS et al : Rehospitalization for heart failure : predict or prevent? Circulation 126 : 501-506, 2012
PubMed
2) Ambrosy, AP et al : Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction : findings from the EVEREST trial. Eur Heart J 34 : 835-843, 2013
PubMed
3) Matsue, Y et al : Time-to-furosemide treatment and mortality in patients hospitalized with acute heart failure. J Am Coll Cardiol 69 : 3042-3051, 2017
PubMed
4) Yoshioka, K et al : Impact of brain natriuretic peptide reduction on the worsening renal function in patients with acute heart failure. PLoS One 15 : e0235493, 2020
PubMed
5) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_d.pdf (2021年10月閲覧)
 
6) Valente, MA et al : Diuretic response in acute heart failure : clinical characteristics and prognostic significance. Eur Heart J 35 : 1284-1293, 2014
PubMed
7) Konstam, MA et al : Effects of oral tolvaptan in patients hospitalized for worsening heart failure : the EVEREST outcome trial. JAMA 297 : 1319-1331, 2007
PubMed
8) Kinugawa, K et al : Effects of tolvaptan on volume overload in patients with heart failure. Int Heart J 59 : 1368-1377, 2018
PubMed
9) Hata, N et al : Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure : the PROTECT multicenter randomized controlled study. Circ J 72 : 1787-1793, 2008
 
10) Bhatt, DL et al : Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384 : 117-128, 2021
PubMed
P.87 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
2) Thiele, H et al : Intra-aortic balloon counterpulsation in acute myocardial infarction complicated by cardiogenic shock (IABP-SHOCK II) : final 12 month results of a randomised, open-label trial. Lancet 382 : 1638-1645, 2013
PubMed
3) Pavlushkov, E et al : Cannulation techniques for extracorporeal life support. Ann Transl Med 5 : 70, 2017
PubMed
4) Seyfarth, M et al : A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 52 : 1584-1588, 2008
PubMed
5) Ouweneel, DM et al : Percutaneous mechanical circulatory support versus intra-aortic balloon pump in cardiogenic shock after acute myocardial infarction. J Am Coll Cardiol 69 : 278-287, 2017
PubMed
6) Nitta, D et al : A useful scoring system for predicting right ventricular assist device requirement among patients with a paracorporeal left ventricular assist device. Int Heart J 59 : 983-990, 2018
PubMed
P.92 掲載の参考文献
1) 日本心不全学会ガイドライン委員会編 : 心不全患者における栄養評価・管理に関するステートメント, 2018. http://www.asas.or.jp/jhfs/pdf/statement20181012.pdf (2021年10月閲覧)
 
2) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会 : 日本版重症患者の栄養療法ガイドライン. 日集中医誌 23 : 185-281, 2016
 
3) 日本集中治療医学会重症患者の栄養管理ガイドライン作成委員会 : 日本版重症患者の栄養療法ガイドライン : 病態別栄養療法. 日集中医誌 24 : 569-591, 2017
 
4) Singer, P et al : ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr 38 : 48-79, 2019
PubMed
5) Rahman, A et al : Identifying critically-ill patients who will benefit most from nutritional therapy : further validation of the "modified NUTRIC" nutritional risk assessment tool. Clin Nutr 35 : 158-162, 2016
PubMed
6) 東別府直紀ほか : 国際栄養調査から見える本邦ICUにおける栄養療法の現状と問題点. 日集中医誌 21 : 243-252, 2014
 
7) Casaer, MP et al : Early versus late parenteral nutrition in critically ill adults. N Engl J Med 365 : 506-517, 2011
PubMed
8) Weijs, PJM et al : Optimal protein and energy nutrition decreases mortality in mechanically ventilated, critically ill patients : a prospective observational cohort study. JPEN J Parenter Enteral Nutr 36 : 60-68, 2012
 
9) 福嶌教偉 : 心臓手術後の患者管理 A to Z 栄養管理. Heart Nursing 17 : 720-725, 2004
 
10) Fuentes, JC et al : Acute and chronic oral magnesium supplementation : effects on endothelial function, exercise capacity, and quality of life in patients with symptomatic heart failure. Congest Heart Fail 12 : 9-13, 2006
PubMed

IV 心不全と不整脈の密接な見解

P.100 掲載の参考文献
1) Hamaguchi, S et al : Mode of death in patients with heart failure and reduced vs. preserved ejection fraction : report from the registry of hospitalized heart failure patients. Circ J 76 : 1662-1669, 2012
PubMed
2) Mitchell, LB : Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias. Curr Opin Cardiol 12 : 33-40, 1997
PubMed
3) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_d.pdf (2021年10月閲覧)
 
4) 日本循環器学会/日本心不全学会 : 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2021年10月閲覧)
 
5) Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure : meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 350 : 1417-1424, 1997
PubMed
6) Bardy, GH et al : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005
 
7) Effect of metoprolol CR/XL in chronic heart failure : Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353 : 2001-2007, 1999
PubMed
8) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II) : a randomised trial. Lancet 353 : 9-13, 1999
 
9) Al-Gobari, M et al : β-blockers for the prevention of sudden cardiac death in heart failure patients : a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 13 : 52, 2013
 
10) Brodine, WN et al : Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). Am J Cardiol 96 : 691-695, 2005
 
11) Chatterjee, S et al : Benefits of β blockers in patients with heart failure and reduced ejection fraction : network meta-analysis. BMJ 346 : 55, 2013
 
12) Okamoto, H et al : Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol : Japanese chronic heart failure (J-CHF) study. Int J Cardiol 164 : 238-244, 2013
PubMed
13) Kober, L et al : A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 333 : 1670-1676, 1995
 
14) Dickstein, K et al : Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction : the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 : 752-760, 2002
PubMed
15) McDonagh, TA et al : 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
16) Pitt, B et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. randomized aldactone evaluation study investigators. N Engl J Med 341 : 709-717. 1999
 
17) Bapoje, SR et al : Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction : a meta-analysis of randomized controlled trials. Circ Heart Fail 6 : 166-173, 2013
PubMed
18) McMurray, JJV et al : Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 : 993-1004, 2014
 
19) Desai, AS et al : Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36 : 1990-1997, 2015
PubMed
20) Curtain, JP et al : Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. Eur Heart J 42 : 3727-3738, 2021
PubMed
21) Fernandes, GC et al : Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure : A meta-analysis of 34 randomized controlled trials. Heart Rhythm 18 : 1098-1105, 2021
PubMed
22) Swedberg, K et al : Ivabradine and outcomes in chronic heart failure (SHIFT) : a randomised placebo-controlled study. Lancet 376 : 875-885, 2010
PubMed
23) Pereira-Barretto AC : Addressing major unmet needs in patients with systolic heart failure : The Role of Ivabradine. Am J Cardiovasc Drugs 16 : 93-101, 2016
PubMed
P.107 掲載の参考文献
1) Reinhardt, SW et al : National trends in the burden of atrial fibrillation during hospital admissions for heart failure. J Am Heart Assoc 10 : e019412, 2021
PubMed
2) Sartipy, U et al : Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. J Am Coll Cardiol HF 5 : 565-574, 2017
 
3) Schnabel, RB et al : Risk assessment for incident heart failure in individuals with atrial fibrillation. Eur J Heart Fail 15 : 843-849, 2013
PubMed
4) Odutayo, A et al : Atrial fibrillation and risks of cardiovascular disease, renal disease, and death : systematic review and meta-analysis. BMJ 354 : i4482, 2016
PubMed
5) An, Y et al : Causes of death in Japanese patients with atrial fibrillation : The Fushimi atrial fibrillation registry. Eur Heart J Qual Care Clin Outcomes 5 : 35-42, 2019
PubMed
6) Santhanakrishnan, R et al : Atrial fibrillation begets heart failure and vice versa : temporal associations and differences in preserved versus reduced ejection fraction. Circulation 133 : 484-492, 2016
PubMed
7) Chamberlain, AM et al : Atrial fibrillation and mortality in heart failure : a community study. Circ Heart Fail 4 : 740-746, 2011
PubMed
8) Mogensen, UM et al : Type of atrial fibrillation and outcomes in patients with heart failure and reduced ejection fraction. J Am Coll Cardiol 70 : 2490-2500, 2017
PubMed
9) Marrouche, NF et al : Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378 : 417-427, 2018
PubMed
10) Prabhu, S et al : Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction : The CAMERA-MRI study. J Am Coll Cardiol 70 : 1949-1961, 2017
PubMed
11) Black-Maier, E et al : Catheter ablation of atrial fibrillation in patients with heart failure and preserved ejection fraction. Heart Rhythm 15 : 651-657, 2018
PubMed
12) Packer, DL et al : Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation : The CABANA randomized clinical trial. JAMA 321 : 1261-1274, 2019
 
13) Packer, DL et al : Ablation versus drug therapy for atrial fibrillation in heart failure : results from the CABANA trial. Circulation 143 : 1377-1390, 2021
PubMed
14) Creta, A et al : Catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy : a European observational multicentre study. Europace 23 : 1409-1417, 2021
PubMed
15) Kirchhof, P et al : Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 383 : 1305-1316, 2020
PubMed
16) Rilling, A et al : Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 144 : 845-858, 2021
 
17) Sohns, C et al : Impact of left ventricular function and heart failure symptoms on outcomes post ablation of atrial fibrillation in heart failure : CASTLE-AF trial. Circ Arrhythm Electrophysiol 13 : e008461, 2020
PubMed
18) Kuck, KH et al : Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure : The randomized AMICA trial. Circ Arrhythm Electrophysiol : e007731, 2019
PubMed
19) Chatterjee, NA et al : Modifiable risk factors for incident heart failure in atrial fibrillation. JACC Heart Fail 5 : 552-560, 2017
PubMed
20) Brignole, M et al : AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS : the APAF-CRT mortality trial. Eur Heart J 42 : 4731-4739, 2021
PubMed
21) Su, L et al : Long-term performance and risk factors analysis after permanent His-bundle pacing and atrioventricular node ablation in patients with atrial fibrillation and heart failure. Europace 22 : ii19-ii26, 2020
PubMed
P.113 掲載の参考文献
1) Agarwal, SK et al : Relation of ventricular premature complexes to heart failure (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol 109 : 105-109, 2012
PubMed
2) Huizar, JF et al : Left ventricular systolic dysfunction induced by ventricular ectopy : a novel model for premature ventricular contraction-induced cardiomyopathy. Circ Arrhythm Electrophysiol 4 : 543-549, 2011
PubMed
3) Wang, Y et al : Cellular mechanism of premature ventricular contraction-induced cardiomyopathy. Heart Rhythm 11 : 2064-2072, 2014
PubMed
4) Smith, ML et al : High-frequency ventricular ectopy can increase sympathetic neural activity in humans. Heart Rhythm 7 : 497-503, 2010
PubMed
5) Kuroki, K et al : Prediction and mechanism of frequent ventricular premature contractions related to haemodynamic deterioration. Eur J Heart Fail 14 : 1112-1120, 2012
PubMed
6) Ruwald, MH et al : Association between frequency of atrial and ventricular ectopic beats and biventricular pacing percentage and outcomes in patients with cardiac resynchronization therapy. J Am Coll Cardiol 64 : 971-981, 2014
PubMed
7) Bogun, F et al : Radiofrequency ablation of frequent, idiopathic premature ventricular complexes : comparison with a control group without intervention. Heart Rhythm 4 : 863-867, 2007
PubMed
8) Cardiac Arrhythmia Suppression Trial (CAST) Investigators : Preliminary report : effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 : 406-412, 1989
 
9) Chen, T et al : Ventricular ectopy in patients with left ventricular dysfunction : should it be treated? J Card Fail 19 : 40-49, 2013
 
10) Ling, Z et al : Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract : prospective randomized study. Circ Arrhythm Electrophysiol 7 : 237-243, 2014
PubMed
P.119 掲載の参考文献
1) Santangeli, P et al : Management of ventricular arrhythmias in patients with advanced heart failure. J Am Coll Cardiol 69 : 1842-1860, 2017
PubMed
2) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
3) 日本循環器学会/日本不整脈心電学会 : 不整脈薬物治療ガイドライン (2020年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/01/JCS2020_Ono.pdf (2021年10月閲覧)
 
4) Davis, J et al : The risk and prevention of sudden death in patients with heart failure with reduced ejection fraction. Curr Opin Cardiol 35 : 138-144, 2020
PubMed
5) Voskoboinik, A et al : Ventricular arrhythmias in heart failure with reduced ejection fraction. Curr Opin Cardiol 35 : 282-288, 2020
PubMed
6) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf (2021年10月閲覧)
 
7) Vaseghi, M et al : Cardiac sympathetic denervation for refractory ventricular arrhythmias. J Am Coll Cardiol 69 : 3070-3080, 2017
PubMed
8) Shah, R et al : Cardiac sympathetic denervation for refractory ventricular arrhythmias in patients with structural heart disease : A systematic review. Heart Rhythm 16 : 1499-1505, 2019
PubMed
9) Hawson, J et al : Renal denervation for the management of refractory ventricular arrhythmias : a systematic review. JACC Clin Electrophysiol 7 : 100-108, 2021
PubMed
10) Herring, N et al : The autonomic nervous system and cardiac arrhythmias : current concepts and emerging therapies. Nat Rev Cardiol 16 : 707-726, 2019
PubMed
P.124 掲載の参考文献
1) Horowitz, LN : The automatic implantable cardioverter defibrillator : Rewiew of clinical results,1980?1990. Pacing Clin Electrophysiol 15 : 604-609, 1992
 
2) Connolly, SJ et al : Meta-analysis of the implantable cardioverter defibrillator secondary prevention trials. AVID, CASH and CIDS studies. Antiarrhythmics vs Implantable Defibrillator study. Cardiac Arrest Study Hamburg. Canadian Implantable Defibrillator Study. Eur Heart J 21 : 2071-2078, 2000
PubMed
3) The Cardiac Arrhythmia Suppression Trial (CAST) Investigators : Preliminary report : effect of encainide and flecainide on mortarity in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321 : 406-412, 1989
 
4) Moss, AJ et al : Improved survival with implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 335 : 1933-1940, 1996
 
5) Buxton, AE et al : A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 341 : 1882-1890, 1999
 
6) Moss, AJ et al : Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 346 : 877-883, 2002
PubMed
7) Bardy, GH et al : Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 352 : 225-237, 2005
 
8) 日本循環器学会/日本不整脈心電学会 : 不整脈非薬物治療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf (2021年10月閲覧)
 
9) Satake, H et al : Current status of primary prevention of sudden cardiac death with implantable cardioverter defibrillator in patients with chronic heart failure--A report from the CHART-2 study. Circ J 79 : 381-390, 2015
PubMed
10) Noda, T et al : Significant impact of electrical storm on mortality in patients with structural heart disease and an implantable cardiac defibrillator. Int J Cardiol 255 : 85-91, 2018
 
11) Rowley, CP et al : Subcutaneous implantable cardioverter defibrillator. Circ Arrhythmia Electrophysiol 5 : 587-593, 2012
PubMed
12) Weiss, R et al : Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation 128 : 944-953, 2013
PubMed
13) Gold, MR et al : Primary results from the understanding outcomes with the S-ICD in primary prevention patients with low ejection fraction (UNTOUCHED) trial. Circulation 143 : 7-17, 2021
 
14) Burke, MC et al : Safety and efficacy of the totally subcutaneous implantable-cardioverter defibrillator ; 2 year results from a pooled analysis of the IDE study and EFFORRLESS registry. J Am Coll Cardiol 65 : 1605-1615, 2015
PubMed
15) Knops, RE et al : Subcutaneous or transvenous defibrillator therapy. N Engl J Med 383 : 526-536, 2020
 

V 心筋疾患による心不全を見逃さない

P.131 掲載の参考文献
1) 日本循環器学会 : 2020年版心アミロイドーシス診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2020_Kitaoka.pdf (2021年10月閲覧)
 
2) Grogan, M et al : Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 68 : 1014-1020, 2016
PubMed
3) Phull, P et al : Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid 25 : 62-67, 2018
PubMed
4) Cyrille, NB et al : Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis. Am J Cardiol 114 : 1089-1093, 2014
PubMed
5) Syed, IS et al : Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC Cardiovasc Imaging 3 : 155-164, 2010
PubMed
6) Maurer, MS et al : Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379 : 1007-1016, 2018
PubMed
P.135 掲載の参考文献
1) Nakao, S et al : An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 333 : 288-293, 1995
PubMed
2) Tanaka, M et al : Identification of Fabry's disease by the screening of alpha-galactosidase A activity in male and female hemodialysis patients. Clin Nephrol 64 : 281-287, 2005
 
3) Rolfs, A et al : Acute cerebrovascular disease in the young : the stroke in young Fabry patients study. Stroke 44 : 340-349, 2013
 
4) Inoue, T et al : Newborn screening for Fabry disease in Japan : prevalence and genotypes of Fabry disease in a pilot study. J Hum Genet 58 : 548-552, 2013
 
5) Mehta, A et al : Fabry Disease : Perspectives from 5 Years of FOS, Oxford PharmaGenesis, Oxford, 157-158, 2006
 
6) Sado, DM et al : Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 6 : 392-398, 2013
PubMed
7) Yamamoto, S et al : Focal reduction in cardiac 123 I-metaiodobenzylguanidine uptake in patients with Anderson-Fabry disease. Circ J 80 : 2550-2551, 2016
PubMed
8) Selvarajah, M et al : Targeted urine microscopy in Anderson-Fabry disease : a cheap, sensitive and specific diagnostic technique. Nephrol Dial Transplant 26 : 3195-3202, 2011
PubMed
9) Laney, DA et al : Fabry disease practice guidelines : recommendations of the National Society of Genetic Counselors. J Genet Couns 22 : 555-564, 2013
PubMed
10) Onoue, K et al : Ultrastructural evidence of glycosphingolipid degradation after enzyme replacement therapy in patients with Fabry disease. Circ J 83 : 2081, 2019
PubMed
11) Onoue, K et al : New treatment for myocardial diseases. J Cardiol 77 : 620-625, 2021
PubMed
P.139 掲載の参考文献
1) 日本サルコイドーシス/肉芽腫性疾患学会 : サルコイドーシス診療の手引き 2020. http://www.jssog.com (2021年11月閲覧)
 
2) Ogura S, et al : Fragmented QRS as a predictor of cardiac events in patients with cardiac sarcoidosis. J Cardiol S0914-5087 (21) 00304-X, 2021 [Online ahead of print]
 
3) 日本心臓核医学会 : 心臓サルコイドーシスに対する18F FDG PET検査の手引き. https://jsnc.org/sites/default/files/2020-12/jsnc-15-3-18.pdf (2021年10月閲覧)
 
4) Uemura, A et al : Histologic diagnostic rate of cardiac sarcoidosis : evaluation of endomyocardial biopsies. Am Heart J 138 : 299-302, 1999
PubMed
5) 日本循環器学会 : 2016年版 心臓サルコイドーシスの診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2016_terasaki_h.pdf (2021年10月閲覧)
 
6) Birnie, DH et al : HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 11 : 1305-1323, 2014
PubMed
7) Yazaki, Y et al : Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 88 : 1006-1010, 2001
PubMed
8) Banba, K et al : Relationship between arrhythmogenesis and disease activity in cardiac sarcoidosis. Heart Rhythm 4 : 1292-1299, 2007
PubMed
9) Bake, MC et al : TNF-alpha inhibition for the treatment of cardiac sarcoidosis. Semin Arthritis Rheum 50 : 546-552, 2020
 
P.144 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 心筋症診療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/08/JCS2018_tsutsui_kitaoka.pdf (2021年10月閲覧)
 
2) Harper, AR et al : Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet 53 : 135-142, 2021
PubMed
3) Ommen, SR et al : 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy : A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 142 : e558-e631, 2020
 
4) Elliott, PM et al : 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy : the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35 : 2733-2779, 2014
 
5) Kitaoka, H et al : Hypertrophic cardiomyopathy-A heterogeneous and lifelong disease in the real world. Circ J 84 : 1218-1226, 2020
PubMed
6) Rowin, EJ et al : Hypertrophic cardiomyopathy with left ventricular apical aneurysm : implications for risk stratification and management. J Am Coll Cardiol 69 : 761-773, 2017
PubMed
7) Rowin, EJ et al : Outcomes in patients with hypertrophic cardiomyopathy and left ventricular systolic dysfunction. J Am Coll Cardiol 75 : 3033-3043, 2020
PubMed
8) Rowin, EJ et al : Role of exercise testing in hypertrophic cardiomyopathy. JACC Cardiovasc Img 10 : 1374-1386, 2017
 
9) Olivotto, I et al : Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM) : a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 396 : 759-769, 2020
PubMed
10) Rowin, EJ et al : Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 136 : 2420-2436, 2017
PubMed
P.149 掲載の参考文献
1) Paterick, TE et al : Left ventricular noncompaction : a diagnostically challenging cardiomyopathy. Circ J 76 : 1556-1562, 2012
PubMed
2) Groeneweg, JA et al : Clinical presentation, long-term follow-up, and outcomes of 1001 arrhythmogenic right ventricular dysplasia/cardiomyopathy patients and family members. Circ Cardiovasc Genet 8 : 437-446, 2015
PubMed
3) Gemayel, C et al : Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 38 : 1773-1781, 2001
PubMed
4) Marcus, FI et al : Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia : proposed modification of the task force criteria. Circulation 121 : 1533-1541, 2010
PubMed
5) Koga, Y et al : A new diagnostic indication device of a biomarker growth differentiation factor 15 for mitochondrial diseases : From laboratory to automated inspection. J Inherit Metab Dis 44 : 358-366, 2021
PubMed
6) Maeda, MH et al : Inflammatory myopathies associated with anti-mitochondrial antibodies. Brain 135 : 1767-1777, 2012
PubMed
7) Albayda, J et al : Inflammatory myopathy associated with anti-mitochondrial antibodies : A distinct phenotype with cardiac involvement. Semin Arthritis Rheum 47 : 552-556, 2018
PubMed
8) Chien, YH et al : Pompe disease : early diagnosis and early treatment make a difference. Pediatr Neonatol 54 : 219-227, 2013
PubMed
9) Hirano, K et al : Triglyceride deposit cardiomyovasculopathy. N Engl J Med 359 : 2396-2398, 2008
PubMed
P.156 掲載の参考文献
1) Iga, K et al : Reversible left ventricular wall motion impairment caused by pheochromocytoma--a case report. Jpn Circ J 53 : 813-818, 1989
PubMed
2) Dote, K et al : [Myocardial stunning due to simultaneous multivessel coronary spasms : a review of 5 cases]. J Cardiol 21 : 203-214, 1991
 
3) Pavin, D et al : Human stress cardiomyopathy mimicking acute myocardial syndrome. Heart 78 : 509-511, 1997
PubMed
4) Ghadri, JR et al : Happy heart syndrome : role of positive emotional stress in Takotsubo syndrome. Eur Heart J 37 : 2823-2829, 2016
PubMed
5) Citro, R et al : Multimodality imaging in Takotsubo syndrome : a joint consensus document of the European Association of Cardiovascular Imaging (EACVI) and the Japanese Society of Echocardiography (JSE). J Echocardiogr 18 : 199-224, 2020
PubMed
6) Lyon, AR et al : Stress (Takotsubo) cardiomyopathy--a novel pathophysiological hypothesis to explain catecholamine-induced acute myocardial stunning. Nat Clin Pract Cardiovasc Med 5 : 22-29, 2008
PubMed
7) Paur, H et al : High levels of circulating epinephrine trigger apical cardiodepression in a β2-adrenergic receptor/Gi-dependent manner : a new model of Takotsubo cardiomyopathy. Circulation 126 : 697-706, 2012
 
8) Okura, H : Update of Takotsubo syndrome in the era of COVID-19. J Cardiol 77 : 361-369, 2021
PubMed
9) Nakano, T et al : Alteration of β-adrenoceptor signaling in left ventricle of acute phase Takotsubo syndrome : a human study. Sci Rep 8 : 12731, 2018
 
10) Okura, H et al : "Hidden" Takotsubo cardiomyopathy in cardiac care unit. J Echocardiogr 18 : 113-116, 2020
PubMed
11) Napp, LC et al : Coexistence and outcome of coronary artery disease in Takotsubo syndrome. Eur Heart J 41 : 3255-3268, 2020
PubMed
12) Eitel, I et al : Clinical characteristics and cardiovascular magnetic resonance findings in stress (Takotsubo) cardiomyopathy. JAMA 306 : 277-286, 2011
PubMed
13) D'Ascenzo, F et al : Impact of aspirin on Takotsubo syndrome : a propensity score-based analysis of the InterTAK Registry. Eur J Heart Fail 22 : 330-337, 2020
 
14) Kagiyama, N et al : Impact of right ventricular involvement on the prognosis of Takotsubo cardiomyopathy. Eur Heart J Cardiovasc Imaging 17 : 210-216, 2016
PubMed
P.160 掲載の参考文献
1) 厚生労働省科学研究難治性疾患政策研究事業「周産期心筋症ガイドライン作成」班/「特発性心筋症に関する調査研究」班編 : 第II章 診断基準. 周産期心筋症診療の手引き, 日本産婦人科学会/日本心不全学会, 中外医学社, 東京, 3-4, 2019
 
2) Kamiya, CA et al : Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy-Circ J 75 : 1975-1981, 2011
PubMed
3) Bello, N et al : The relationship between pre-eclampsia and peripartum cardiomyopathy : a systematic review and meta-analysis. J Am Coll Cardiol 62 : 1715-1723, 2013
PubMed
4) 日本妊娠高血圧学会 : 妊娠高血圧症候群新定義・臨床分類. https://jsshp.jp/journal/pdf/20180625_Teigi_Kaiteian.pdf (2022年1月閲覧)
 
5) Hilfiker-Kleiner, D et al : A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128 : 589-600, 2007
PubMed
6) Patten, IS et al : Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485 : 333-338, 2012
PubMed
7) Otani, K et al : Deficiency of cardiac natriuretic peptide signaling promotes peripartum cardiomyopathy-like remodeling in the mouse heart. Circulation 141 : 571-588, 2020
PubMed
8) Ware, JS et al : Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med 374 : 233-241, 2016
PubMed
9) Pfeffer, TJ et al : Increased cancer prevalence in peripartum cardiomyopathy. JACC CardioOncol 1 : 196-205, 2019
 
10) Arrigo, M et al : Bromocriptine for the treatment of peripartum cardiomyopathy : welcome on BOARD. Eur Heart J 38 : 2680-2682, 2017
PubMed
11) Hilfiker-Kleiner, D et al : Bromocriptine for the treatment of peripartum cardiomyopathy : a multicentre randomized study. Eur Heart J 38 : 2671-2679, 2017
PubMed
P.167 掲載の参考文献
1. Zamorano, JL et al : 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines : The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37 : 2768-2801, 2016
 
1) Murabito, A et al : Mechanisms of anthracycline-induced cardiotoxicity : Is mitochondrial dysfunction the answer? Front Cardiovasc Med 7 : 35, 2020
PubMed
2) JPLSG長期フォローアップ委員会長期フォローアップガイドライン作成ワーキンググループ編/前田美穂責任編集 : 小児がん治療後の長期フォローアップガイドライン. 医薬ジャーナル社, 大阪, 333, 2013
 
2. Onishi, T et al : Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction. J Echocardiogr 19 : 1-20, 2021
 
3. Alexandre, J et al : Cardiovascular toxicity related to cancer treatment : a pragmatic approach to the American and European Cardio-Oncology Guidelines. J Am Heart Assoc 9 : e018403, 2020
 
3) Macedo, AVS et al : Efficacy of dexrazoxane in preventing anthracycline cardiotoxicity in breast cancer. JACC CardioOncol 1 : 68-79, 2019
 
4) Thavendiranathan, P et al : Strain-guided management of potentially cardiotoxic cancer therapy. J Am Coll Cardiol 77 : 392-401, 2021
PubMed
5) McDonagh, TA et al : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
6) Lee, DH et al : Cardiovascular complications of multiple myeloma treatment : evaluation, management, and prevention. Curr Treat Options Cardiovasc Med 20 : 19, 2018
 
7) Hahn, VS et al : Heart failure with targeted cancer therapies : mechanisms and cardioprotection. Circ Res 128 : 1576-1593, 2021
PubMed
8) Kadowaki, H et al : Mechanisms and management of immune checkpoint inhibitor-related cardiac adverse events. JMA J 4 : 91-98, 2021
PubMed
9) Matsui, H et al : A fatal case of myocarditis following myositis induced by pembrolizumab treatment for metastatic upper urinary tract urothelial carcinoma. Int Heart J 61 : 1070-1074, 2020
PubMed
10) Waliany, S et al : Myocarditis surveillance with high-sensitivity troponin I during cancer treatment with immune checkpoint inhibitors. JACC CardioOncol 3 : 137-139, 2021
PubMed
P.174 掲載の参考文献
1) Aoyama, N et al : National survey of fulminant myocarditis in Japan : therapeutic guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a scientific committee). Circ J 66 : 133-144, 2002
PubMed
2) Sawamura, A et al : Early prediction model for successful bridge to recovery in patients with fulminant myocarditis supported with percutaneous venoarterial extracorporeal membrane oxygenation-Insights From the CHANGE PUMP Study. Circ J 82 : 699-707, 2018
PubMed
3) Ferreira, VM et al : Cardiovascular magnetic resonance in nonischemic myocardial inflammation : expert recommendations. J Am Coll Cardiol 72 : 3158-3176, 2018
PubMed
4) Nishii, M et al : Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol 44 : 1292-1297, 2004
PubMed
5) Lee, CH et al : Predictive factors of a fulminant course in acute myocarditis. Int J Cardiol 109 : 142-145, 2006
PubMed
6) 日本循環器学会ほか : 循環器病の診断と治療に関するガイドライン (2008年度合同研究班報告) 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2009_izumi_h.pdf (2021年11月閲覧)
 
7) Backer, DD et al : Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362 : 779-789, 2010
 
8) Winter, MP et al : Immunomodulatory treatment for lymphocytic myocarditis-a systematic review and meta-analysis. Heart Fail Rev 23 : 573-581, 2018
PubMed
9) Arima, M et al : Serum levels of eosinophil cationic protein in patients with eosinophilic myocarditis. Int J Cardiol 84 : 97-99, 2002
PubMed
10) Kandolin, R et al : Diagnosis, treatment, and outcome of giant-cell myocarditis in the era of combined immunosuppression. Circ Heart Fail 6 : 15-22, 2013
PubMed
11) Moslehi, JJ et al : Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet 391 : 933, 2018
PubMed

VI 合併症とその治療戦略

P.181 掲載の参考文献
1) 伊藤浩 : 糖尿病と心不全 : その治療に迫る. 日内会誌 108 : 1902-1911, 2019
 
2) Packer, M : Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs. Cardiovasc Diabetol 19 : 62, 2020
 
3) Packer, M : Potentiation of insulin signaling contributes to heart failure in type 2 diabetes : a hypothesis supported by both mechanistic studies and clinical trials. JACC Basic Transl Sci 3 : 415-419, 2018
PubMed
4) Cosmi, F et al : Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail 20 : 888-895, 2018
PubMed
5) 〔特集〕糖尿病と心不全の新パラダイム-かつての常識はもはや通用しない? -. 糖尿病プラクティス 37 (2), 2020
 
6) 野出孝一監/豊田茂ほか編著 : ひと味違うSGLT2阻害薬の使い方. 中外医学社, 東京, 2020
 
7) Packer, M : Is metformin beneficial for heart failure in patients with type 2 diabetes? Diabetes Res Clin Pract 136 : 168-170, 2018
PubMed
8) 日本循環器学会・日本糖尿病学会合同委員会編 : 糖代謝異常者における循環器病の診断・予防・治療に関するコンセンサスステートメント, 日本循環器学会, 日本糖尿病学会監, 南江堂, 東京, 2020
 
P.185 掲載の参考文献
1) Sakima, A et al : Optimal blood pressure targets for patients with hypertension : a systematic review and meta-analysis. Hypertens Res 42 : 483-495, 2019
PubMed
2) Beckett, NS et al : Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358 : 1887-1898, 2008
 
3) Wright, JT Jr et al : A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373 : 2103-2116, 2015
PubMed
4) Okamoto, R et al : Effects of lowering diastolic blood pressure to < 80 mmHg on cardiovascular mortality and events in patients with coronary artery disease : a systematic review and meta-analysis. Hypertens Res 42 : 650-659, 2019
PubMed
5) Zhang, K et al : Diastolic blood pressure reduction contributes more to the regression of left ventricular hypertrophy : a meta-analysis of randomized controlled trials. J Hum Hypertens 27 : 698-706, 2013
 
6) Soliman, EZ et al : Effect of intensive blood pressure lowering on left ventricular hypertrophy in patients with hypertension : SPRINT (Systolic Blood Pressure Intervention Trial). Circulation 136 : 440-450, 2017
PubMed
7) Lewis, CE et al : Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med 384 : 1921-1930, 2021
PubMed
8) ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group : Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic : The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288 : 2981-2997, 2002
PubMed
9) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone : the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 283 : 1967-1975, 2000
 
10) Davis, BR et al : Role of diuretics in the prevention of heart failure : the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Circulation 113 : 2201-2210, 2006
PubMed
11) Davis, BR et al : Heart failure with preserved and reduced left ventricular ejection fraction in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Circulation 118 : 2259-2267, 2008
PubMed
12) Ohishi, M et al : Analysis of antihypertensive treatment using real-world Japanese data-the retrospective study of antihypertensives for lowering blood pressure (REAL) study. Hypertens Res 42 : 1057-1067, 2019
PubMed
P.189 掲載の参考文献
1) Silverberg, DS et al : Erythropoietin should be part of congestive heart failure management. Kidney Int Suppl 87 : S40-S47, 2003
PubMed
2) Adlbrecht, C et al : Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 29 : 2343-2350, 2008
 
3) Nanas, JN et al : Etiology of anemia in patients with advanced heart failure. J Am Coll Cardiol 48 : 2485-2489, 2006
PubMed
4) McDonagh, TA et al : 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42 : 3599-3726, 2021
PubMed
5) Yancy, CW et al : 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation 136 : e137-e161, 2017
 
6) Rocha, BML et al : The burden of iron deficiency in heart failure : therapeutic approach. J Am Coll Cardiol 71 : 782-793, 2018
PubMed
7) Okuno, K et al : Effective blood hemoglobin level to predict prognosis in heart failure with preserved left ventricular ejection fraction : results of the Japanese heart failure syndrome with preserved ejection fraction registry. Heart Vessels 34 : 1168-1177, 2019
PubMed
8) Tsutsui, H et al : JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure-digest version. Circ J 83 : 2084-2184, 2019
 
9) Naito, Y et al : Iron and cardiovascular diseases. J Cardiol 77 : 160-165, 2021
PubMed
10) Chertow, GM et al : Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med 384 : 1589-1600, 2021
PubMed
P.195 掲載の参考文献
1) Silverberg, D et al : The cardio-renal anaemia syndrome : Does it exist? Nephrol Dial Transplant 18 : viii7-viii12, 2003
PubMed
2) Rangaswami, J et al : Cardiorenal syndrome : classification, pathophysiology, diagnosis, and treatment strategies : a scientific statement from the American Heart Association. Circulation 139 : e840-e878, 2019
PubMed
3) 日本腎臓学会編 : CKD診療ガイド 2012. 日腎会誌 54 : 1031-1191, 2012
 
4) House, AA et al : Heart failure in chronic kidney disease : conclusions from a kidney disease : Improving Global Outcomes (KDIGO) controversies conference. Kidney Int 95 : 1304-1317, 2019
PubMed
5) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
6) Rangaswami, J et al : Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease : a scientific statement from the American Heart Association. Circulation 142 : e265-e286, 2020
PubMed
7) Thomas, MM et al : 2021 update to the 2017 ACC Expert Consensus Decision Pathway for optimization of heart failure treatment : answers to 10 pivotal issues about heart failure with reduced ejection fraction : a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77 : 772-810, 2021
 
8) Mullens, W et al : Evaluation of kidney function throughout the heart failure trajectory-a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22 : 584-603, 2020
 
9) Armstrong, PW et al : Vericiguat in patients with heart failure and reduced ejection fraction. New Engl J Med 382 : 1883-1893, 2020
PubMed
10) Cice, G et al : Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy : a prospective, placebo-controlled trial. J Am Coll Cardiol 41 : 1438-1444, 2003
 
11) Hein, AM et al : Medical management of heart failure with reduced ejection fraction in patients with advanced renal disease. Jacc Hear Fail 7 : 371-382, 2019
 
12) Fu, L et al : Do implantable cardioverter defibrillators reduce mortality in patients with chronic kidney disease at all stages? Int Heart J 58 : 371-377, 2017
 
13) Zhou, Q et al : Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca2+ release. Nat Med 17 : 1003-1009, 2011
PubMed
14) Haynes, R et al : Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease. Circulation 138 : 1505-1514, 2018
PubMed
15) Zannad, F et al : Efficacy and safety of sodium zirconium cyclosilicate for hyperkalaemia : the randomized, placebo-controlled HARMONIZE-global study. Esc Heart Fail 7 : 54-64, 2020
PubMed
16) Filippatos, G et al : Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol 78 : 142-152, 2021
PubMed
17) 南野哲男編 : 循環器診療コンプリートシリーズ 心不全 心・腎・脳の視点でとらえる循環器疾患, 学研メディカル秀潤社, 東京, 60-76, 2021
 
18) 日本腎臓学会編 : エビデンスに基づくCKD診療ガイドライン 2018. 日腎会誌 60 : 1037-1193, 2018
 
19) Sen, J et al : Tolvaptan for heart failure in chronic kidney disease patients : a systematic review and meta-analysis. Heart Lung Circ 27 : 928-939, 2018
PubMed
20) Hitomi, Y et al : Characterization of tolvaptan response and its impact on the outcome for patients with heart failure. J Cardiol 78 : 285-293, 2021
PubMed
P.199 掲載の参考文献
1) Pellikka, PA et al : Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111 : 3290-3295, 2005
PubMed
2) Mack, JM et al : Transcatheter aortic-valve replacement with a balloon expandable valve in low-risk patients. N Engl J Med 380 : 1695-1705, 2019
 
3) Thyregod, HGH et al : Five-year clinical and echocardiographic outcomes from the Nordic Aortic Valve Intervention (NOTION) randomized clinical trial in lower surgical risk patients. Circulation 2019 Feb 1. doi : 10.1161/CIRCULATIONAHA.118.036606. Online ahead of print.
 
4) 日本循環器学会/日本胸部外科学会/日本血管外科学会/日本心臓血管外科学会 : 2020年改訂版 弁膜症治療のガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Izumi_Eishi.pdf (2021年11月閲覧)
 
5) Noguchi, M et al : Clinical outcomes of transcatheter aortic valve implantation (TAVI) in nonagenarians from the optimized catheter valvular intervention-TAVI registry. Catheter Cardiovasc Interv 97 : E113-E120, 2021
PubMed
6) Galatas, C et al : Transcatheter aortic valve replacement over age 90 : Risks vs benefits. Clin Cardiol 43 : 156-162, 2020
PubMed
7) Shimura, T et al : Impact of the clinical frailty scale on outcomes after transcatheter aortic valve replacement. Circulation 135 : 2013-2024, 2017
PubMed
8) Komaki, K et al : Preoperative frailty affects postoperative complications, exercise capacity, and home discharge rates after surgical and transcatheter aortic valve replacement. Heart Vessels 36 : 1234-1245, 2021
PubMed
9) 日本循環器学会/日本心不全学会 : 2021年改訂版 循環器疾患における緩和ケアについての提言. https://www.j-circ.or.jp/cms/wpcontent/uploads/2021/03/JCS2021_Anzai.pdf (2021年11月閲覧)
 
10) 日本循環器学会/日本アミロイドーシス学会/日本血液学会/日本心エコー図学会/日本心臓病学会/日本心不全学会/日本不整脈心電学会/厚生労働省 難治性疾患政策研究事業「アミロイドーシスに関する調査研究班」/厚生労働省 難治性疾患政策研究事業「特発性心筋症に関する調査研究」研究班 : 2020年版 心アミロイドーシス診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2020_Kitaoka.pdf (2021年11月閲覧)
 
P.204 掲載の参考文献
1) 北村順 : 循環器医が知っておくべき漢方薬, 文光堂, 東京, 2013
 
2) 北村順 : 続 循環器医が知っておくべき漢方薬, 文光堂, 東京, 2017
 
3) 北村順 : 循環器診療で使える漢方薬. Medicina 58 : 69-73, 2021
 
4) 寺澤捷年 : 症例から学ぶ和漢診療学, 第3版, 医学書院, 東京, 24, 2012
 
5) 田代眞一 : 漢方薬はなぜ効くか-現代薬理学からの解明-. Prog Med 14 : 1774-1791, 1994
Medical*Online
6) Kurita, T et al : Effects of Gorei-san : a traditional Japanese kampo medicine, on aquaporin 1, 2, 3, 4 and V2R mRNA expression in rat kidney and forebrain. J Med Sci 11 : 30-38, 2011
 
7) Sato, H : Electropharmacological actions of the constituents of Sinomeni Caulis et Rhizome and Mokuboi-to in guinea pig heart. Am J Chin Med 33 : 967-979, 2005
 
8) 小川恵子 : 現代医学における漢方医学の役割. 金沢大学十全医学会雑誌 126 : 13-17, 2017
Medical*Online
9) 加藤士郎ほか : 慢性閉塞性肺疾患における3大参耆剤の臨床的有用性. 漢方医学 40 : 172-176, 2016
 
10) 本間行彦ほか : かぜ症候群に対する麻黄附子細辛湯の有用性-封筒法による比較試験-. 日本東洋医学雑誌 47 : 245-252, 1996
 
P.208 掲載の参考文献
1) Yoshihisa, A et al : Sleep disordered breathing and cardiovascular diseases. J Atheroscler Thromb 26 : 315-327, 2019
PubMed
2) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
3) 日本呼吸器学会/厚生労働科学研究費補助金難治性疾患政策研究事業「難治性呼吸器疾患・肺高血圧症に関する調査研究」班監/睡眠時無呼吸症候群 (SAS) の診療ガイドライン作成委員会編 : 睡眠時無呼吸症候群 (SAS) の診療ガイドライン 2020, 南江堂, 東京, 2020
 
4) 百村伸一ほか : 循環器病の診断と治療に関するガイドライン (2008-2009年度合同研究班報告) 【ダイジェスト版】循環器領域における睡眠呼吸障害の診断・治療に関するガイドライン. Circ J 74 : 1053-1084, 2010
 
5) 日本呼吸器学会NPPVガイドライン作成委員会編 : NPPV (非侵襲的陽圧換気療法) ガイドライン, 改訂第2版, 南江堂, 東京, 2015
 
6) Cowie, MR et al : Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med 373 : 1095-1105, 2015
PubMed
P.213 掲載の参考文献
1) Benjamin, EJ et al : Heart disease and stroke statistics-2017 update : a report from the American Heart Association. Circulation 135 : e146-e603, 2017
PubMed
2) 日本循環器学会 : 非心臓手術における合併心疾患の評価と管理に関するガイドライン (2014年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2014_kyo_h.pdf (2021年10月閲覧)
 
3) Fleisher, LA et al : ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery : a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) : developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 116 : e418-e499, 2007
 
4) Kristensen, SD et al : 2014 ESC/ESA guidelines on non-cardiac surgery : cardiovascular assessment and management : the Joint Task Force on non-cardiac surgery : cardiovascular assessment and management of the European Society of Cardiology and the European Society of Anesthesiology. Eur Heart J 35 : 2383-2431, 2014
 
5) 黒岩政之ほか : 肥大型心筋症を有する患者の周術期心血管合併症の検討. 麻酔 52 : 733-739, 2003
 
6) Warnes, CA at al : ACC/AHA 2008 guidelines for the management of adults with congenital heart disease : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to develop guidelines on the management of adults with congenital heart disease). Circulation 118 : e714-e833, 2008
 
7) Cannesson, M et al : Anesthesia for noncardiac surgery in adults with congenital heart disease. Anesthesiology 111 : 432-440, 2009
PubMed
8) Fleisher, LA et al : 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery : executive summary : a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation 130 : 2215-2245, 2014
 
9) Benjamin, JL et al : Association of left ventricular ejection fraction and symptoms with mortality after elective noncardiac surgery among patients with heart failure. JAMA 321 : 572-579, 2019
 

VII 心不全再入院を予防する治療戦略

P.219 掲載の参考文献
1) Miller, WL : Fluid volume overload and congestion in heart failure : Time to reconsider pathophysiology and how volume is assessed. Circ Heart Fail 9 : e002922, 2016
PubMed
2) Hall, JE : Guyton and Hall Textbook of Medical Physiology, 12th ed, Saunders, Philadelphia, 296-300, 2011
 
3) Boorsma, EM et al : Congestion in heart failure : a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 17 : 641-655, 2020
 
4) Nijst, P et al : The pathophysiological role of interstitial sodium in heart failure. J Am Coll Cardiol 65 : 378-388, 2015
PubMed
P.223 掲載の参考文献
1) Hollenberg, SM et al : 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure : A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 74 : 1966-2011, 2019
 
2) Jujo, K et al : Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure. ESC Heart Fail 3 : 177-188, 2016
PubMed
3) Pitt, B et al : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 : 709-717, 1999
 
4) Pitt, B et al : Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 : 1383-1392, 2014
PubMed
5) McMurray, JJV et al : Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381 : 1995-2008, 2019
PubMed
6) Lee, PC et al : Weight loss associated with sodium-glucose cotransporter-2 inhibition : a review of evidence and underlying mechanisms. Obes Rev 19 : 1630-1641, 2018
 
P.228 掲載の参考文献
1) Belardinelli, R et al : 10-year exercise training in chronic heart failure : a randomized controlled trial. J Am Coll Cardiol 60 : 1521-1528, 2012
PubMed
2) O'Connor, CM et al : Efficacy and safety of exercise training in patients with chronic heart failure : HF-ACTION randomized controlled trial. JAMA 301 : 1439-1450, 2009
PubMed
3) Raat, W et al : Impact of primary care involvement and setting on multidisciplinary heart failure management : a systematic review and meta-analysis. ESC Heart Fail 8 : 802-818, 2021
PubMed
4) Izawa, H et al : Standard cardiac rehabilitation program for heart failure. Circ J 83 : 2394-2398, 2019
PubMed
5) Kamiya, K et al : Nationwide survey of multidisciplinary care and cardiac rehabilitation for patients with heart failure in Japan-an analysis of the AMED-CHF study. Circ J 83 : 1546-1552, 2019
PubMed
6) Thomas, RJ et al : Home-based cardiac rehabilitation : a scientific statement from the American Association of Cardiovascular and Pulmonary Rehabilitation, the American Heart Association, and the American College of Cardiology. Circulation 140 : e69-e89, 2019
 
P.233 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年度改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
2) Zipes, DP et al : Braunwald's Heart Disease : A Textbook of Cardiovascular Medicine, 11th ed, Elsevier, Amsterdam, 2019
 
3) 日本心不全学会編 : 急性・慢性心不全診療ガイドライン かかりつけ医向けガイダンス, 日本心不全学会, 2019
 
4) Thibodeau, JT et al : Characterization of a novel symptom of advanced heart failure : Bendopnea. JACC Heart Failure 2 : 24-31, 2014
PubMed
5) Thibodeau, JT et al : Bendopnea and risk of adverse clinical outcomes in ambulatory patients with systolic heart failure. Am Heart J 183 : 102-107, 2017
PubMed
6) Guyton, AC et al : Textbook of Medical Physiology, 11th ed, Elsevier Saunders, Amsterdam, 2006
 
7) Onishi, K : Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. J Cardiol 70 : 128-134, 2017
PubMed
8) Tanabe, N et al : Emphysema distribution and annual changes in pulmonary function in male patients with chronic obstructive pulmonary disease. Respir Res 13 : 31, 2012
PubMed
9) Fallick, C et al : Sympathetically mediated changes in capacitance : redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 4 : 669-675, 2011
PubMed
P.238 掲載の参考文献
1) Tsutsui, H et al : Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. Circ J 70 : 1617-1623, 2006
PubMed
2) 厚生労働省 : 脳卒中. 心臓病その他の循環器病に係る診療提供体制の在り方に関する検討会 : 脳卒中, 心臓病その他の循環器病に係る診療体制の在り方について. 2017. https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000173149.pdf (2021年11月閲覧)
 
3) Schiff, GD et al : Decompensated heart failure : symptoms, patterns of onset, and contributing factors. Am J Med 114 : 625-630, 2003
PubMed
4) Nohria, A et al : Clinical assessment identifies hemodynamic profiles that predict outcomes in patients admitted with heart failure. J Am Coll Cardiol 41 : 1797-1804, 2003
PubMed
5) Mebazaa, A et al : Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 36 : S129-S139, 2008
PubMed
6) Krumholz, HM et al : Resuscitation preferences among patients with severe congestive heart failure : results from the SUPPORT project. study to understand prognoses and preferences for outcomes and risks of treatments. Circulation 98 : 648-655, 1998
PubMed
P.243 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年10月閲覧)
 
2) McAlister, FA et al : Multidisciplinary strategies for the management of heart failure patients at high risk for admission : a systematic review of randomized trials. J Am Coll Cardiol 44 : 810-819, 2004
PubMed
3) 日本脳卒中学会/日本循環器学会ほか : 脳卒中と循環器病克服第二次5ヵ年計画 ストップCVD (脳心血管病) 健康長寿を達成するために. 2021年3月. https://www.j-circ.or.jp/five_year/files/JCS_five_year_plan_2nd.pdf (2021年10月閲覧)
 
P.249 掲載の参考文献
1) Okura, Y et al : Impending epidemic : future projection of heart failure in Japan to the year 2055. Circ J 72 : 489-491, 2008
 
2) 厚生労働省 : 緩和ケア診療加算等の要件の見直し. 中央社会保険医療協議会 総会 (第386回) 議事次第, 256-258, 平成30年1月24日. https://www.mhlw.go.jp/stf/shingi2/0000191961.html (2021年11月閲覧)
 
3) 厚生労働省保険局医療課長/厚生労働省保険局歯科医療管理官 : 基本診療科の施設基準及びその届出に関する手続きの取り扱いについて. 保医発0305 第2号, 令和2年3月5日. https://kouseikyoku.mhlw.go.jp/kinki/shinsei/shido_kansa/shisetsu_kijun_teirei/000152303.pdf (2021年11月閲覧)
 
4) 日本循環器学会/日本心不全学会 : 2021年改訂版 循環器疾患における緩和ケアについての提言. https://www.j-circ.or.jp/cms/wpcontent/uploads/2021/03/JCS2021_Anzai.pdf (2021年11月閲覧)
 
5) 日本循環器学会/日本心不全学会 : 2021年JCS/JHFSガイドラインフォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2021年11月閲覧)
 
6) 厚生労働省 : 脳卒中, 心臓病その他の循環器病に係る診療提供体制の在り方に関する検討会 : 脳卒中, 心臓病その他の循環器病に係る診療提供体制の在り方について. 2017. http://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000173149.pdf (2021年11月閲覧)
 
7) World Health Organization (WHO) : Palliative care (緩和ケアの定義). 2002. https://www.who.int/health-topics/palliative-care (2021年11月閲覧)
 
8) Allen, LA et al : Decision making in advanced heart failure : a scientific statement from the American Heart Association. Circulation 125 : 1928-1952, 2012
PubMed
9) Sobanski, PZ et al : Palliative care for people living with heart failure : European Association for Palliative Care Task Force expert position statement. Cardiovasc Res 116 : 12-27, 2020
PubMed
10) Writing Committee ; Maddox, TM et al : 2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment : Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction : A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 77 : 772-810, 2021
 
11) NHS End of Life Care : Advance Care Planning : A Guide for Health and Social Care Staff. https://www.stlukes-hospice.org.uk/wp-content/uploads/2017/06/ACP-Guide-for-Health-and-Social-Care-Staff-.pdf (2022年1月閲覧)
 
12) 日本医師会 : 終末期医療 アドバンス・ケア・プランニング (ACP) から考える. 2018年4月. http://www.med.or.jp/doctor/rinri/i_rinri/006612.html (2021年11月閲覧)
 
13) 厚生労働省 : 地域包括ケアシステムの推進 (検討の方向性). https://www.mhlw.go.jp/content/12300000/000691738.pdf (2022年1月閲覧)
 
14) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2022年1月閲覧)
 
15) 日本緩和医療学会 : がん患者の呼吸器症状の緩和に関するガイドライン 2016年度版. https://www.jspm.ne.jp/guidelines/respira/2016/index.php (2021年11月閲覧)
 
16) 日本医師会監 : 新版 がん緩和ケアガイドブック, 青海社, 東京, 2017
 
17) 日本緩和医療学会 : がん患者の治療抵抗性の苦痛と鎮静に関する基本的な考え方の手引き 2018年版. https://www.jspm.ne.jp/guidelines/sedation/2018/index.php (2021年11月閲覧)
 
18) Hamatani, Y et al : Development and practical test of quality indicators for palliative care in patients with chronic heart failure. Circ J 84 : 584-591, 2020
PubMed
P.253 掲載の参考文献
1) Okura, Y et al : Impending epidemic : future projection of heart failure in Japan to the year 2055. Circ J 72 : 489-491, 2008
 
2) Tsuchihashi, M et al : Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart failure. Am Heart J 142 : e7, 2001
PubMed
3) Rich, MW et al : A multidisciplinary intervention to prevent the readmission of elderly patients with congestive heart failure. N Engl J Med 333 : 1190-1195, 1995
PubMed
4) Chaudhry, SI et al : Telemonitoring for patients with chronic heart failure : a systematic review. J Card Fail 13 : 56-62, 2007
PubMed
5) Chaudhry, SI et al : Telemonitoring in patients with heart failure. N Engl J Med 363 : 2301-2309, 2010
PubMed
6) Koehler, F et al : Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure : the telemedical interventional monitoring in heart failure study. Circulation 123 : 1873-1880, 2011
 
7) Kotooka, N et al : The first multicenter, randomized, controlled trial of home telemonitoring for Japanese patients with heart failure : home telemonitoring study for patients with heart failure (HOMES-HF). Heart Vessels 33 : 866-876, 2018
PubMed
8) Drews, TEI et al : Non-invasive home telemonitoring in patients with decompensated heart failure : a systematic review and meta-analysis. ESC Heart Fail 8 : 3696-3708, 2021
PubMed
9) Koehler, F et al : Efficacy of telemedical interventional management in patients with heart failure (TIM-HF2) : a randomised, controlled, parallel-group, unmasked trial. Lancet 392 : 1047-1057, 2018
PubMed
10) 日本循環器学会/日本心不全学会 : 2021年 JCS/JHFSガイドライン フォーカスアップデート版 急性・慢性心不全診療. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Tsutsui.pdf (2021年10月閲覧)
 
11) Kikuchi, A et al : Feasibility of home-based cardiac rehabilitation using an integrated telerehabilitation platform in elderly patients with heart failure : A pilot study. J Cardiol 78 : 66-71, 2021
PubMed
12) Adamson, PB : Pathophysiology of the transition from chronic compensated and acute decompensated heart failure : new insights from continuous monitoring devices. Curr Heart Fail Rep 6 : 287-292, 2009
PubMed
13) Chaudhry, SI et al : Patterns of weight change preceding hospitalization for heart failure. Circulation 116 : 1549-1554, 2007
PubMed
14) Imamura, T et al : Advances in hemodynamic monitoring in heart failure patients. Intern Med 60 : 167-171, 2021
PubMed
15) Abraham, WT et al : Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy : complete follow-up results from the CHAMPION randomised trial. Lancet 387 : 453-461, 2016
PubMed
16) Lindenfeld, J et al : Haemodynamic-guided management of heart failure (GUIDE-HF) : a randomised controlled trial. Lancet 398 : 991-1001, 2021
PubMed
17) Yamakawa, N : Cardiac acoustic biomarkers as surrogate markers to diagnose the phenotypes of pulmonary hypertension : an exploratory study. Heart Vessels 2021 Oct 1. doi : 10.1007/s00380-021-01943-7. Online ahead of print.
 

VIII 心不全診療で活かす検査

P.260 掲載の参考文献
1) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年11月閲覧).
 
2) 日本循環器学会 : 慢性冠動脈疾患診断ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2018_yamagishi_tamaki.pdf (2021年11月閲覧)
 
3) Tanabe, Y et al : Computed tomographic evaluation of myocardial ischemia. Jpn J Radiol 38 : 411-433, 2020
PubMed
4) Tanabe, Y et al : Impact of knowledge-based iterative model reconstruction on myocardial late iodine enhancement in computed tomography and comparison with cardiac magnetic resonance. Int J Cardiovasc Imaging 33 : 1609-1618, 2017
PubMed
5) 日本循環器学会 : 2020年版 心アミロイドーシス診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2020_Kitaoka.pdf (2021年11月閲覧)
 
6) Roy, C et al : Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction. J Cardiovasc Magn Reson 20 : 55, 2018
PubMed
7) Kinoshita, M et al : Left ventricular longitudinal strain is a major determinant of CT-derived three-dimensional maximum principal strain : comparison with two-dimensional speckle tracking echocardiography. Heart Vessels 2021 Jul 7. doi : 10.1007/s00380-021-01901-3. Online ahead of print.
 
8) Kurata, A et al : On-site computed tomography-derived fractional flow reserve using a machine-learning algorithm-clinical effectiveness in a retrospective multicenter cohort. Circ J 83 : 1563-1571, 2019
 
9) 日本循環器学会/日本心不全学会 : 心筋症診療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/08/JCS2018_tsutsui_kitaoka.pdf (2021年11月閲覧)
 
P.266 掲載の参考文献
1) McCrohon, JA et al : Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 108 : 54-59, 2003
PubMed
2) Adabag, AS et al : Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 51 : 1369-1374, 2008
PubMed
3) Chan, RH et al : Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. Circulation 130 : 484-495, 2014
PubMed
4) Patel, MR et al : Detection of myocardial damage in patients with sarcoidosis. Circulation 120 : 1969-1977, 2009
PubMed
5) Vogelsberg, H et al : Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis : noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 51 : 1022-1030, 2008
PubMed
6) Kwong, RY et al : Incidence and prognostic implication of unrecognized myocardial scar characterized by cardiac magnetic resonance in diabetic patients without clinical evidence of myocardial infarction. Circulation 118 : 1011-1020, 2008
PubMed
7) Vincenti, G et al : Stress perfusion CMR in patients with known and suspected CAD : prognostic value and optimal ischemic threshold for revascularization. JACC Cardiovasc Imaging 10 : 526-537, 2017
PubMed
8) Nagel, E et al : Magnetic resonance perfusion or fractional flow reserve in coronary disease. N Engl J Med 380 : 2418-2428, 2019
 
9) Puntmann, VO et al : T1-mapping and outcome in nonischemic cardiomyopathy : all-cause mortality and heart failure. JACC Cardiovasc Imaging 9 : 40-50, 2016
PubMed
10) Wong, TC et al : Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35 : 657-664, 2014
PubMed
11) Puntmann, VO et al : Native T1 and ECV of noninfarcted myocardium and outcome in patients with coronary artery disease. J Am Coll Cardiol 71 : 766-778, 2018
PubMed
P.271 掲載の参考文献
1) Jacobson, AF et al : Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 55 : 2212-2221, 2010
PubMed
2) Nakata, T et al : A pooled analysis of multicenter cohort studies of (123) I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. JACC Cardiovasc Imaging 6 : 772-784, 2013
PubMed
3) Merlet, P et al : Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 33 : 471-477, 1992
PubMed
4) Ogita, H et al : Prognostic significance of cardiac (123) I metaiodobenzylguanidine imaging for mortality and morbidity in patients with chronic heart failure : a prospective study. Heart 86 : 656-660, 2001
PubMed
5) Verberne, HJ et al : Prognostic valure of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure : a systematic review. Eur Heart J 29 : 1147-1159, 2008
 
6) Tamaki, S et al : Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction : results from a comparative study with signal-averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol 53 : 426-435, 2009
PubMed
7) Seo, M et al : Prognostic significance of cardiac I-123-metaiodobenzylguanidine imaging in patients with reduced, mid-range, and preserved left ventricular ejection fraction admitted for acute decompensated heart failure : a prospective study in Osaka Prefectural Acute Heart Failure Registry (OPAR). Eur Heart J Cardiovasc Imaging 22 : 58-66, 2021
PubMed
8) Kayama, K et al : Incremental prognostic value of cardiac metaiodobenzylguanidine imaging over the co-morbid burden in acute decompensated heart failure. ESC Heart Fail 8 : 1167-1177, 2021
PubMed
9) Okuda, K et al : Semi-automated algorithm for calculating heart-to-mediastinum ratio in cardiac Iodine-123 MIBG imaging. J Nucl Cardiol 18 : 82-89, 2011
PubMed
10) Nakajima, K et al : A prediction model for 5-year cardiac mortality in patients with chronic heart failure using 123I- metaiodobenzylguanidine imaging. Eur J Nucl Med Mol Imaging 41 : 1673-1682, 2014
 
P.277 掲載の参考文献
1) Lang, RM et al : Recommendations for cardiac chamber quantification by echocardiography in adults : an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 : 1-39, 2015
PubMed
2) Rossi, A et al : Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. J Am Coll Cardiol 40 : 1425, 2002
PubMed
3) Kawata, T et al : Echocardiographic assessment of right ventricular function in routine practice : Which parameters are useful to predict one-year outcome in advanced heart failure patients with dilated cardiomyopathy? J Cardiol 70 : 316-322, 2017
PubMed
4) Rossi, A et al : Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy. Heart 97 : 1675-1680, 2011
PubMed
5) Jung, IH et al : Left ventricular global longitudinal strain as a predictor for left ventricular reverse remodeling in dilated cardiomyopathy. J Cardiovasc Imaging 28 : 137-149, 2020
PubMed
6) Ishiwata, J et al : Combined evaluation of right ventricular function using echocardiography in non-ischaemic dilated cardiomyopathy. ESC Heart Fail 8 : 3947-3956, 2021
PubMed
7) Ypenburg, C et al : Myocardial contractile reserve predicts improvement in left ventricular function after cardiac resynchronization therapy. Am Heart J 154 : 1160-1165, 2007
PubMed
8) Aimo, A et al : Imaging, biomarker, and clinical predictors of cardiac remodeling in heart failure with reduced ejection fraction. JACC Heart Fail 7 : 782-794, 2019
PubMed
9) Pivetta, E et al : Lung ultrasound integrated with clinical assessment for the diagnosis of acute decompensated heart failure in the emergency department : a randomized controlled trial. Eur J Heart Fail 21 : 754-766, 2019
 
10) Volpicelli, G et al : Bedside ultrasound of the lung for the monitoring of acute decompensated heart failure. Am J Emerg Med 26 : 585-591, 2008
PubMed
P.281 掲載の参考文献
1) 日本循環器学会/日本心臓リハビリテーション学会 : 2021年改訂版 心血管疾患における心臓リハビリテーションに関するガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Makita.pdf (2021年11月閲覧)
 
2) Stringer, WW et al : Cardiac output estimated noninvasively from oxygen uptake during exercise. J Appl Physiol 82 : 908-912, 1997
PubMed
3) Mancini, DM et al : Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 83 : 778-786, 1991
PubMed
4) Koike, A et al : Detecting abnormalities in left ventricular function during exercise by respiratory measurement. Circulation 80 : 1737-1746, 1989
PubMed
5) Ainsworth, BE et al : 2011 Compendium of Physical Activities : a second update of codes and MET values. Med Sci Sports Exerc 43 : 1575-1581, 2011
PubMed
6) Forman, DE et al : 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. J Am Coll Cardiol 60 : 2653-2661, 2012
PubMed
7) Du, H et al : A review of the six-minute walk test : its implication as a self-administered assessment tool. Eur J Cardiovasc Nurs 8 : 2-8, 2009
 
8) Kamiya, K et al : Gait speed has comparable prognostic capability to six-minute walk distance in older patients with cardiovascular disease. Eur J Prev Cardiol 25 : 212-219, 2018
PubMed
9) Del Buono, MG et al : Exercise intolerance in patients with heart failure : JACC State-of-the-art review. J Am Coll Cardiol 73 : 2209-2225, 2019
PubMed
10) Kamiya, K et al : Multidisciplinary cardiac rehabilitation and long-term prognosis in patients with heart failure. Circ Heart Fail 13 : e006798, 2020
PubMed
P.285 掲載の参考文献
1) Rossignol, P et al : Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 22 : 1378-1389, 2020
PubMed
2) Rosano, GMC et al : Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors : coordinated by the working group on cardiovascular pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother 4 : 180-188, 2018
 
3) Gheorghiade, M et al : Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure : an analysis from the OPTIMIZE-HF registry. Eur Heart J 28 : 980-988, 2007
PubMed
4) Yancy, CW et al : 2013 ACCF/AHA guideline for the management of heart failure : a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 128 : e240-e327, 2013
 
5) Suzuki, S et al : Prognostic significance of high-sensitivity cardiac troponin in patients with heart failure with preserved ejection fraction. Heart Vessels 34 : 1650-1656, 2019
PubMed
6) Anand, IS et al : C-reactive protein in heart failure : prognostic value and the effect of valsartan. Circulation 112 : 1428-1434, 2005
PubMed
7) Nishimoto, Y et al : C-reactive protein at discharge and 1-year mortality in hospitalised patients with acute decompensated heart failure : an observational study. BMJ Open 10 : e041068, 2020
PubMed
8) Itagaki, T et al : Inflammation-based assessment for the risk stratification of mortality in patients with heart failure. Sci Rep 11 : 14989, 2021
PubMed
9) Kato, T et al : Association with Controlling Nutritional Status (CONUT) score and in-hospital mortality and infection in acute heart failure. Sci Rep 10 : 3320, 2020
PubMed
10) Kato, T et al : Association of an increase in serum albumin levels with positive 1-year outcomes in acute decompensated heart failure : a cohort study. PLoS One 15 : e0243818, 2020
PubMed
11) Oki, Y et al : High serum uric acid is highly associated with a reduced left ventricular ejection fraction rather than increased plasma B-type natriuretic peptide in patients with cardiovascular diseases. Sci Rep 9 : 682, 2019
PubMed
P.290 掲載の参考文献
1) 心筋生検研究会編 : 診断モダリティとしての心筋病理, 南江堂, 東京, 2017
 
2) Leone, O et al : 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovascular Pathology 21 : 245-274, 2012
 
3) Cooper, LT et al : The role of endomycardial biopsy in the management of cardiovascular disease : a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Circulation 116 : 2216-2233, 2007
 
4) Seferovic, PM et al : Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. J Card Fail 27 : 727-743, 2021
 
5) 日本循環器学会 : 急性および慢性心筋炎の診断・治療に関するガイドライン (2009年改訂版). https://www.j-circ.or.jp/cms/wpcontent/uploads/2020/02/JCS2009_izumi_h.pdf (2021年12月閲覧)
 
6) 日本循環器学会/日本心不全学会 : 心筋症診療ガイドライン (2018年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2018/08/JCS2018_tsutsui_kitaoka.pdf (2021年12月閲覧)
 
7) 日本循環器学会/日本心不全学会 : 急性・慢性心不全診療ガイドライン (2017年改訂版). https://www.j-circ.or.jp/cms/wp-content/uploads/2017/06/JCS2017_tsutsui_h.pdf (2021年12月閲覧)
 
8) Caforio, AL et al : Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis : a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34 : 2636-2648, 2013
 
9) 大郷恵子 : 拡張型心筋症. 病理と臨床 39 : 964-968, 2021
Medical*Online
10) 松山高明ほか : 心内膜心筋生検標本の診断と所見の記載方法. 診断病理 31 : 75-87, 2014
Medical*Online
P.294 掲載の参考文献
1) Guyton, AC : Circulatory Physiology : Cardiac Output and Its Regulation, W. B. Saunders, Philadelphia, 1963
 
2) Guyton, AC et al : Textbook of Medical Physiology, 9th edition, W. B. Saunders, Philadelphia, 1995
 
3) 岸拓弥ほか : 血圧とは? -血圧の生理-. 新・心臓病診療プラクティス 11 高血圧を識る・個別診療に活かす, 苅尾七臣ほか編, 文光堂, 東京, 8-13, 2008
 
4) Shoukas, AA et al : Control of total systemic vascular capacity by the carotid sinus baroreceptor reflex. Circ Res 33 : 22-33, 1973
PubMed
5) Sakamoto, T et al : Changes in vascular properties, not ventricular properties, predominantly contribute to baroreflex regulation of arterial pressure. Am J Physiol Heart Circ Physiol 308 : H49-H58, 2015
 
6) Funakoshi, K et al : Striking volume intolerance is induced by mimicking arterial baroreflex failure in normal left ventricular function. J Card Fail 20 : 53-59, 2014
PubMed
7) Suga, H : Time course of left ventricular pressure-volume relationship under various enddiastolic volume. Jpn Heart J 10 : 509-515, 1969
PubMed
8) Sunagawa, K et al : Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol 245 : H773-H780, 1983
PubMed

書評

最近チェックした商品履歴

Loading...